Parcourir par auteur "Anastasilakis, A. D."
Voici les éléments 1-5 de 5
-
Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappa B ligand levels in women with established osteoporosis treated with teriparatide
Anastasilakis, A. D.; Goulis, D. G.; Polyzos, S. A.; Gerou, S.; Pavlidou, V.; Koukoulis, G.; Avramidis, A. (2008)Objective: The mechanisms regulating the anabolic response of the skeleton to intermittent exogenous parathyroid hormone (PTH) administration are not fully elucidated. The aim of this prospective study was to evaluate the ... -
Effect of Exogenous Intermittent Recombinant Human PTH 1-34 Administration and Chronic Endogenous Parathyroid Hormone Excess on Glucose Homeostasis and Insulin Sensitivity
Anastasilakis, A. D.; Efstathiadou, Z.; Plevraki, E.; Koukoulis, G. N.; Slavakis, A.; Kita, M.; Avramidis, A. (2008)We aimed to evaluate the effects of exogenous intermittent teriparatide (rhPTH 1-34) administration versus the chronic exposure to excess endogenous parathyroid hormone (PTH), as in pHPT, on glucose homeostasis. Two patient ... -
Endogenous intact PTH is suppressed during teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis
Anastasilakis, A. D.; Polyzos, S. A.; Goulis, D. G.; Slavakis, A.; Efstathiadou, Z.; Kita, M.; Koukoulis, G.; Avramidis, A. (2008)Introduction: Teriparatide (recombinant human PTH 1-34/TPTD) is an osteoanabolic agent available for osteoporosis treatment. The aim of this prospective trial was to evaluate the acute and chronic effects of TPTD in ... -
Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial
Anastasilakis, A. D.; Goulis, D. G.; Polyzos, S. A.; Gerou, S.; Koukoulis, G. N.; Efstathiadou, Z.; Kita, M.; Avramidis, A. (2008)Aims: We aimed to compare the effect of risedronate (RIS) and teriparatide (TPTD) (recombinant human parathyroid hormone 1-34) on bone turnover markers in women with postmenopausal osteoporosis. Methods: Forty-four Caucasian ... -
Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: A randomized, controlled trial
Anastasilakis, A. D.; Goulis, D. G.; Polyzos, S. A.; Gerou, S.; Koukoulis, G.; Kita, M.; Avramidis, A. (2008)Risedronate and teriparatide have opposite actions on the osteoblast-osteoclast dipole and are expected to influence the RANK/RANKL/ osteoprotegerin (OPG) system. We aimed to evaluate changes in serum OPG and RANKL after ...